45
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To define the role of rare variants in advanced age-related macular degeneration (AMD) risk, we sequenced the exons of 681 genes within AMD-associated loci and pathways in 2,493 cases and controls. We first tested each gene for increased or decreased burden of rare variants in cases compared to controls. We found that 7.8% of AMD cases compared to 2.3% of controls are carriers of rare missense CFI variants (OR=3.6, p=2×10 −8). There was a predominance of dysfunctional variants in cases compared to controls. We then tested individual variants for association to disease. We observed significant association with rare missense alleles outside CFI. Genotyping in 5,115 independent samples confirmed associations to AMD with a K155Q allele in C3 (replication p=3.5×10 −5, OR=2.8; joint p=5.2×10 −9, OR=3.8) and a P167S allele in C9 (replication p=2.4×10 −5, OR=2.2; joint p=6.5×10 −7, OR=2.2). Finally, we show that the 155Q allele in C3 results in resistance to proteolytic inactivation by CFH and CFI. These results implicate loss of C3 protein regulation and excessive alternative complement activation in AMD pathogenesis, thus informing both the direction of effect and mechanistic underpinnings of this disorder.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence of age-related macular degeneration in the United States.

          To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender. Summary prevalence estimates of drusen 125 microm or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD. The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy. More than 7 million individuals had drusen measuring 125 microm or larger and were, therefore, at substantial risk of developing AMD. Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020. Age-related macular degeneration was far more prevalent among white than among black persons. Age-related macular degeneration affects more than 1.75 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to almost 3 million by 2020.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

            Association studies offer a potentially powerful approach to identify genetic variants that influence susceptibility to common disease, but are plagued by the impression that they are not consistently reproducible. In principle, the inconsistency may be due to false positive studies, false negative studies or true variability in association among different populations. The critical question is whether false positives overwhelmingly explain the inconsistency. We analyzed 301 published studies covering 25 different reported associations. There was a large excess of studies replicating the first positive reports, inconsistent with the hypothesis of no true positive associations (P < 10(-14)). This excess of replications could not be reasonably explained by publication bias and was concentrated among 11 of the 25 associations. For 8 of these 11 associations, pooled analysis of follow-up studies yielded statistically significant replication of the first report, with modest estimated genetic effects. Thus, a sizable fraction (but under half) of reported associations have strong evidence of replication; for these, false negative, underpowered studies probably contribute to inconsistent replication. We conclude that there are probably many common variants in the human genome with modest but real effects on common disease risk, and that studies using large samples will convincingly identify such variants.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease

              More than a thousand disease susceptibility loci have been identified via genome-wide association studies (GWAS) of common variants; however, the specific genes and full allelic spectrum of causal variants underlying these findings generally remain to be defined. We utilize pooled next-generation sequencing to study 56 genes in regions associated to Crohn’s Disease in 350 cases and 350 controls. Follow up genotyping of 70 rare and low-frequency protein-altering variants (MAF ~ .001-.05) in nine independent case-control series (16054 CD patients, 12153 UC patients, 17575 healthy controls) identifies four additional independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant association to a novel, protective splice variant in CARD9 (p < 1e-16, OR ~ 0.29), as well as additional associations to coding variants in IL18RAP, CUL2, C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by providing novel, rare, and likely functional variants that will empower functional experiments and predictive models.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                17 October 2013
                15 September 2013
                November 2013
                01 May 2014
                : 45
                : 11
                : 1366-1370
                Affiliations
                [1 ]Ophthalmic Epidemiology and Genetics Service, New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USA.
                [2 ]Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA.
                [3 ]Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts, USA.
                [4 ]Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
                [5 ]Center for Human Disease Modeling, Duke University, Durham, North Carolina, USA.
                [6 ]Departments of Cell Biology, Duke University, Durham, North Carolina, USA.
                [7 ]Pediatrics, Duke University, Durham, North Carolina, USA.
                [8 ]Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts, USA.
                [9 ]Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA
                [10 ]Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
                [11 ]Institute of Genetic Medicine, Newcastle University, International Centre for Life, Newcastle upon Tyne, UK
                [12 ]Hôpital Intercommunal de Créteil, Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France
                [13 ]Division of Genetics, Brigham and Women’s Hospital, Boston, Massachusetts, USA.
                [14 ]Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts, USA.
                [15 ]Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
                Author notes
                [* ]Please send correspondence to: 800 Washington St. #450 Tufts Medical Center Boston, Massachusetts 02111 United States of America jseddon@ 123456tuftsmedicalcenter.org 617-636-9000 (tel) 617-636-5844 (fax)
                [* ]77 Avenue Louis Pasteur Harvard New Research Building, Suite 250D Boston, Massachusetts 02446 United States of America soumya@ 123456broadinstitute.org 617-525-4484 (tel) 617-525-4488 (fax)
                Article
                NIHMS512112
                10.1038/ng.2741
                3902040
                24036952
                22ada43d-db9d-4ec3-86c3-48eb6507bee7

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
                Award ID: R01 AR062886 || AR
                Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
                Award ID: K08 AR055688 || AR
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article